EuroBiotech: More Articles of Note


> Gadeta, a Dutch biotech partnered with Kite, named former AnaptysBio chief medical officer Marco Londei as its CEO. Londei’s appointment coincided with the receipt of FDA clearance to start a clinical trial in multiple myeloma. Statement (PDF)

> MorphoSys hit pause on enrollment in a phase 1/2 trial of MOR202 in response to COVID-19. The German biotech plans to continue enrolling patients “in studies with the potential for significant benefit in life-threatening indications.” Release

> Oryzon linked vafidemstat to a reduction in agitation and aggression in patients with Alzheimer’s disease. Analysts at Jefferies said the clinical trial “demonstrated encouraging efficacy.” Statement

Virtual Roundtable

ASCO Explained: Expert predictions and takeaways from the world's biggest cancer meeting

Join FiercePharma for our ASCO pre- and post-show webinar series. We'll bring together a panel of experts to preview what to watch for at ASCO. Cancer experts will highlight closely watched data sets to be unveiled at the virtual meeting--and discuss how they could change prescribing patterns. Following the meeting, we’ll do a post-show wrap up to break down the biggest data that came out over the weekend, as well as the implications they could have for prescribers, patients and drugmakers.

> A COVID-19 patient in Israel received RedHill Biopharma’s opaganib on a compassionate use basis. Interest in the drug in COVID-19 patients is underpinned by preclinical evidence of antiviral activity. Release 

> MaxCyte said COVID-19 may delay clinical development of its mRNA-based cell therapy candidate. The London-listed company “is evaluating the potential for reduced R&D spend during the current financial period.” Statement

> Imophoron disclosed work on a COVID-19 vaccine it thinks may be more specific than prophylactics in development at other companies. The vaccine candidates are ready for preclinical testing. Release 

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.